Nivolumab-associated cutaneous T-cell lymphoma

Nivolumab is a human monoclonal antibody used to treat malignancies, including melanoma, non-small cell lung cancer, and advanced renal cell carcinoma (RCC).1 Nivolumab acts via inhibition of T-lymphocytes by targeting the programmed cell death-1 receptor.2 Despite the checkpoint inhibitor's success in treatment response, immunomodulatory therapies are not without risks, as programmed cell death-1 inhibition has led to immune-related cutaneous adverse events, including rash (14.3%), pruritus (13.2%), and, in severe cases (1.4%), Steven Johnson syndrome/toxic epidermal necrolysis.